Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer.
Cancers (Basel)
; 16(1)2024 Jan 01.
Article
en En
| MEDLINE
| ID: mdl-38201636
ABSTRACT
BACKGROUND/AIM:
Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer. MATERIALS ANDMETHODS:
A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients.RESULTS:
Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer.CONCLUSIONS:
High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Cancers (Basel)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Grecia